Integrating patient and public involvement and engagement in translational medicine
- PMID: 39128476
- DOI: 10.1016/S0140-6736(24)01552-6
Integrating patient and public involvement and engagement in translational medicine
Conflict of interest statement
OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC) West Midlands Birmingham, NIHR Applied Research Collaboration (ARC) West Midlands, BTRU-PCT, LifeArc, UK Research and Innovation (UKRI), Health Foundation, Merck, Anthony Nolan, Gilead Sciences, Sarcoma UK, and GSK and declares personal fees from Gilead Sciences, Merck, and GSK. PB is a Jenner Institute Investigator and an Affiliate Faculty Member of the Duke Human Vaccine Institute; receives funding from the NIH, National Institute of Allergy and Infectious Diseases, Division of AIDS, and NIHR BTRU-PCT; has received personal fees from Gilead Sciences; and has a family member who is employed by and owns shares in GSK. MJC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient Reported Outcomes Research, and is an NIHR Senior Investigator; receives funding from the NIHR, UKRI, NIHR Birmingham BRC, NIHR BTRU-PCT, LifeArc, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR ARC West Midlands, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Merck, Anthony Nolan, GSK and Gilead; has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute, Genentech, Vertex, ICON, Halfloop, and Pfizer; and has a family member who owns shares in GSK. RC receives funding from NIHR BTRU-PCT and Oxford NIHR BRC; is on the Advisory Board of Novartis and Accelerating Clinical Trials; has received consulting fees for Accelerating Clinical Trials; and has received speaking honoraria from Miltenyi and Malinkrodt Pharmaceuticals. SEH receives funding from the NIHR, UKRI, Rinri Therapeutics, and Anthony Nolan and declares personal fees from Cochlear, AstraZeneca, Pfizer, CIS Oncology, and Aparito. FAMK receives research funding from Gilead and personal fees from Therakos, Sanofi, Mallinkrodt, and Vertex. CM receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre, UKRI, CIS Oncology, and Anthony Nolan and declares personal fees from Aparito. KLS receives funding from NIHR BTRU-PCT and Anthony Nolan. VY receives funding from NIHR BTRU-PCT. FK receives funding from NIHR BTRU-PCT and NIHR BRC. All other authors declare no competing interests. EC and J-RA are patient authors. We thank James O J Davies and all members of the BTRU-PCT, including patient and public partners, for their support in developing the strategies described in this Comment. This Comment discusses work funded by the NIHR at BTRU-PCT (reference: NIHR 203339). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care.
References
LinkOut - more resources
Full Text Sources